Nov 4, 2024 04:05PM
Aug 19, 2024 07:01AM
Aug 19, 2024 07:00AM
Feb 27, 2024 04:05PM
Nov 8, 2023 04:05PM
Nov 2, 2023 07:06AM
Nov 2, 2023 07:00AM Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Aug 4, 2022 04:01PM
Aug 4, 2022 04:01PM
May 9, 2022 04:05PM
May 9, 2022 04:05PM
Feb 28, 2022 04:05PM
Feb 28, 2022 04:05PM
Feb 22, 2022 08:07AM Supernus Pharma (SUPN) Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
Feb 22, 2022 08:00AM
Feb 22, 2022 08:00AM
Nov 3, 2021 04:01PM
Nov 3, 2021 04:01PM
Sep 3, 2021 05:55AM
Sep 2, 2021 06:45PM
Sep 2, 2021 06:45PM Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
Feb 25, 2021 04:00PM
Feb 25, 2021 04:00PM
Feb 22, 2021 08:03AM
Feb 22, 2021 08:00AM
Feb 22, 2021 08:00AM
Nov 3, 2020 04:30PM
Nov 3, 2020 04:30PM Supernus Announces Third Quarter 2020 Financial Results
Aug 18, 2020 06:06PM
Aug 18, 2020 06:06PM
May 5, 2020 06:46PM
May 5, 2020 06:46PM
Feb 25, 2020 04:40PM
Feb 25, 2020 04:40PM
Jan 21, 2020 06:33PM Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
Jan 21, 2020 06:33PM
May 24, 2018 04:28PM
Jun 16, 2016 04:33PM
Jun 16, 2016 04:30PM
Oct 22, 2015 06:21PM
Oct 22, 2015 06:21PM

15,414 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All